Skip to main content

Charles P. Venditti, M.D., Ph.D.

Senior Investigator, Genetics and Molecular Biology Branch
Head, Organic Acid Research Section

Scientific Summary

The research interests of the section surround the genetics, pathophysiology and treatment of the hereditary methylmalonic acidemias and disorders of intracellular cobalamin metabolism. These inherited enzymopathies belong to the organic acidemia category of metabolic disease, and represent a group of collectively common inborn errors of metabolism. Affected patients are medically fragile and suffer from multisystemic complications, including severe metabolic instability, stroke of the basal ganglia, pancreatitis, end stage renal failure, growth impairment, osteoporosis and developmental delay. Despite intensive study since the early 1960s, few patients with MMA have survived into adulthood and evidence for effectiveness of current medical therapies is lacking, a fact that stands in stark contrast to the practice of screening all U.S. newborns for MMA. Because these disorders also feature pathology that can be seen in many common conditions, such as vitamin B12 deficiency, stroke syndromes, pancreatic dysfunction, diabetes, chronic kidney disease, osteoporosis, obesity and retinal degeneration, it is likely that the careful elucidation of patient phenotypes will provide new insights into the pathophysiology of more complex and prevalent disorders, and perhaps, suggest new pathways to target for therapeutic interventions in these more common conditions.

Figure 1: An overview of the pathway of cobalamin uptake, transport and intracellular metabolism.
Figure 1

Through our natural history protocol, "Clinical and Basic Investigations of Methylmalonic Acidemia and Related Disorders" ( Identifier: NCT00078078), the Venditti lab has enrolled the largest single-center patient cohort. In the past few years, they have described dental manifestations in MMA, whole-body energetics in MMA, and a new treatment approach for cobalamin C deficiency. They have delineated the neurocognitive phenotype displayed by MMA patients and described the natural history of renal growth in MMA. The team has authored a series of comprehensive reviews on the clinical phenotype and treatment of isolated MMA, cobalamin disorders, and propionic academia, as well as numerous book chapters related to the diagnosis and management of patients with branched chain amino acid oxidation disorder.

Clinical investigations conducted by the section have enabled the identification of two new inborn errors of metabolism: combined malonic-methylmalonic acidemia (CMAMMA) and cblX deficiency. These discoveries have led to the demonstration of a new metabolic pathway for organic acid metabolism in humans and defined the first example of transcriptional dysregulation as the cause of a classical inborn error of metabolism. Both examples serve to further emphasize the novel insights into intermediary metabolism that can be achieved through the study of MMA. The longer-term goals of our clinical efforts are to study the correlations between enzymatic, genotypic, clinical and metabolic variables with phenotype, disease manifestations and outcomes in MMA and cobalamin disorders; to critically evaluate current treatment practices and develop evidence-based guidelines; and to discover and characterize novel patient phenotypes.

Figure 2: Growth and phenotypic correction after AAV8-mMut gene therapy, adapted from Chandler and Venditti (2010) Mol Ther 18: 11-16. Download as PDF.
Figure 2

Other than dietary management, no therapeutic alternative to elective liver or liver-kidney organ transplantation exists for patients with isolated MMA. We have therefore studied the efficacy of gene therapy as a treatment for MMA. After preliminary/feasibility experiments of gene correction using lenti- and adenovirus-mediated gene delivery, the section engineered a series of adeno-associated viral (AAV) vectors to express the methylmalonyl-CoA mutase (Mut) gene systemically or only in hepatocytes. The results in all the studies are striking: while the untreated Mut-/- mice uniformly perish in early life, the Mut-/- mice that receive AAV gene therapy with any of the section's AAV vectors have near normal long-term survival, are phenotypically corrected and display sustained, low-level enzymatic activity for as long as one year after a single treatment with an AAV vector. Our gene therapy experiments also inspired the invention of a device and method to quantify whole-body Mut enzyme activity after gene therapy using 13C isotopomer metabolism. The gene delivery approach and monitoring platform the team has developed should be immediately translatable to a phase I/II gene therapy trial at the NIH Clinical Center using AAV to treat mut MMA patients and could provide precedence for the application of a similar approach to many other disorders of intermediary metabolism, particularly those that feature mitochondrial localization of the metabolic lesion.  

In the laboratory, researchers in the section have generated a suite of clinically-relevant mouse models to dissect disease mechanisms in MMA. Using a knock-out allele of Mut, they have established that mitochondrial dysfunction is central to the pathology of MMA and have extended these observations using ion abrasion scanning electron microscopy to characterize hepatic mitochondria in MMA on the nanometer scale in 3-D. To recapitulate the organ specific pathology experienced by patients with MMA, they created a new mouse model, Mut-/-;TgINS-Alb-Mut, to replicate the renal manifestations seen in MMA, specifically progressive kidney failure associated with impairment of proximal tubular mitochondrial function. These mice, like MMA patients who have received a liver transplant, express the Mut enzyme only in the hepatocytes. RNA profiling of genes expressed in the mutant mouse kidneys has identified novel MMA-associated renal biomarkers that we have validated in our patient cohort and used to measure the response of MMA kidney disease to antioxidant therapy. This mouse model has also been used to develop and test new therapeutics and should be useful for the wider study of related medical conditions, especially chronic kidney failure caused by tubulointerstitial disease. Future efforts to apply murine and zebrafish modeling to other disorders in the pathway, including cblC deficiency, are in progress.

Organic Acid Research Section Members

Madeline Arnold
Randy J. Chandler, Ph.D., Staff Scientist
Katherine Ellis
Susan Ferry
Jack Gagne
Brandon Hubbard
Alexander Lesser
Lina Li, Research Scientist
Irini Manoli, M.D., Ph.D., Staff Clinician
Kelsey Murphy
Alexandra Pass, Fellow
Jessica Schneller
Oleg Shchelochkov
Jennifer L. Sloan, Ph.D., M.S., Protocol Coordinator and Genetic Counselor
Stephanie Smith

Top of page

Last Updated: March 14, 2017